Article
Geriatrics & Gerontology
Robert MacLachlan, Patrick Gavin Kehoe, J. Scott Miners
Summary: The activity of angiotensin-converting enzyme-1 (ACE-1) is induced in the early stages of Alzheimer's disease (AD), independently from the normal physiological changes in ACE-1 protein during aging.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2022)
Article
Clinical Neurology
Malik Nassan, Iyas Daghlas, Ignazio S. Piras, Emily Rogalski, Lianne M. Reus, Yolande Pijnenburg, Leah K. Cuddy, Richa Saxena, M-Marsel Mesulam, Matt Huentelman
Summary: This study used genetic approaches to find that angiotensin-converting enzyme (ACE) inhibition is associated with Alzheimer's disease and frontotemporal dementia, but not with Lewy body dementia or vascular dementia. These results provide evidence for further research on the neurocognitive effects of ACE inhibition.
ALZHEIMERS & DEMENTIA
(2023)
Article
Chemistry, Multidisciplinary
Moaz M. Abdou, Dewen Dong, Paul M. O'Neill, Eric Amigues, Magdalini Matziari
Summary: In drug discovery, molecular modification of lead molecules is crucial for drug development. This study reports the synthesis of a novel RXPA380-proline hybrid, which showed lower inhibition of ACE compared to the parent compound RXPA380.
Review
Cell Biology
Filipa Gouveia, Antoni Camins, Miren Ettcheto, Joana Bicker, Amilcar Falcao, M. Teresa Cruz, Ana Fortuna
Summary: Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by Tau hyperphosphorylation and A beta deposits. Recent scientific evidence suggests that age-related vascular alterations and cardiovascular risk factors play a role in the development of AD. Drugs targeting the Renin Angiotensin System (RAS) have the potential to delay AD development due to their effects on brain RAS. The ACE 1/Ang II/AT1R axis in AD is believed to have detrimental effects, while the alternative axis ACE 1/Ang II/AT2R; ACE 2/Ang (1 7)/MasR; Ang IV/AT4R (IRAP) seems to have beneficial effects on memory and cognition. Retrospective studies and pre-clinical studies support the therapeutic potential of RAS drugs for AD.
AGEING RESEARCH REVIEWS
(2022)
Article
Medicine, Research & Experimental
Mauro G. Silva, Gerardo R. Corradi, Juan Perez Duhalde, Myriam Nunez, Eliana M. Cela, Daniel H. Gonzales Maglio, Ana Brizzio, Martin R. Salazar, Walter G. Espeche, Mariela M. Gironacci
Summary: This study found that COVID-19 patients have higher levels of ACE2 expression and enzymatic activity in their blood compared to healthy individuals, while levels of AngII and Ang-(1-7) are lower. Even when excluding COVID-19 patients under RAS blockade treatment, ACE2 expression and enzymatic activity remain higher in COVID-19 patients, suggesting the involvement of RAS in COVID-19.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Ming-Hui Yang, Tzu-Chuan Ho, Chin-Chuan Chang, Yuh-Shan Su, Cheng-Hui Yuan, Kuo-Pin Chuang, Yu-Chang Tyan
Summary: Two types of ACE inhibitors, lisinopril and benazepril HCl, were found to upregulate LRP1B and 14-3-3 protein ζ/δ in neuroblastoma cells. Benazepril HCl also increased the expression of calreticulin. These findings suggest that ACE inhibitors may have potential in treating Alzheimer's disease by promoting neuronal cell survival independently of their antihypertensive effect.
Article
Pharmacology & Pharmacy
Taikang Yao, Zhenchao Wu, Zilu Wang, Liting Chen, Beibei Liu, Ming Lu, Ning Shen
Summary: Observational studies and meta-analyses have shown a positive correlation between the use of angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer. The study used Mendelian randomization to verify the associations between ACE inhibition, ACEI-induced cough, and the risk of lung cancer. The results indicate a significant relationship between ACE inhibition and the development of lung cancer, as well as a higher risk of lung cancer for Europeans with ACEI-induced cough.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Steven D. Brooks, Rachel L. Smith, Aline S. Moreira, Hans C. Ackerman
Summary: Lisinopril increases ACE2 expression in tissues relevant to COVID-19, while adding losartan prevents the lisinopril-induced increase. A sex difference was observed with higher ACE2 levels in the kidneys of male mice.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Neurosciences
Judy Ghalayini, Gabrielle L. Boulianne
Summary: Recent studies have shown that certain antihypertensive drugs like ACE inhibitors and ARBs can reduce the incidence and progression of Alzheimer's disease. However, the reason why these drugs are effective in some patients and not others, independent of their blood pressure regulation role, remains unclear. Understanding the mechanisms behind this is essential for developing effective AD therapeutics.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Pharmacology & Pharmacy
Gemma Garcia-Lluch, Carmen Pena-Bautista, Lucrecia Moreno Royo, Miguel Baquero, Antonio Jose Canada-Martinez, Consuelo Chafer-Pericas
Summary: This case-control study examines the role of antihypertensive medication in the prevention of Alzheimer's Disease (AD). The results suggest that angiotensin II receptor blockers may play a potential role in neuroprotection and AD prevention.
Review
Integrative & Complementary Medicine
Rakhi Chakraborty, Swarnendu Roy
Summary: Research has identified many plants with ACE inhibitory activity, some of which show potent inhibition. Bioactive metabolites isolated from these plants exhibit significant ACE inhibitory activity as well as beneficial antioxidant, antidiabetic, antihyperlipidemic, and anti-inflammatory properties.
JOURNAL OF INTEGRATIVE MEDICINE-JIM
(2021)
Article
Multidisciplinary Sciences
Jakub Jankowski, Hye Kyung Lee, Julia Wilflingseder, Lothar Hennighausen
Summary: This study reports on the genetic programs activated in kidney cells in response to interferons during COVID-19, and the inhibitory effect of a Janus kinase inhibitor. The findings help identify kidney-specific interferon responses.
Article
Cell Biology
Chun Xu, Debra Garcia, Yongke Lu, Kaysie Ozuna, Donald A. Adjeroh, Kesheng Wang
Summary: This study examines the associations of angiotensin-converting enzyme-1 (ACE1) and apolipoproteins (APOs) with Alzheimer's disease (AD), cardiovascular diseases (CVDs), and endocrine-metabolic diseases (EMDs). The study finds that certain APO proteins and ACE1 levels are associated with AD, MCI, CVD, and EMD.
Review
Pharmacology & Pharmacy
Saeed Alshahrani
Summary: Chronic kidney disease is a complex condition with various underlying causes. Current pharmacotherapeutic treatment options aim to slow disease progression and improve quality of life but cannot achieve complete cure. The first-line treatment for controlling blood pressure in chronic kidney disease is the use of renin-angiotensin-aldosterone system modulators. These modulators, including direct renin inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers, have different structures and mechanisms of action, leading to varying treatment outcomes. The choice of modulator depends on patient presentation, comorbidities, treatment availability and affordability, and healthcare provider expertise. Comparative studies between these modulators are currently lacking, which could provide valuable information for healthcare providers and researchers. This review compares the direct renin inhibitor (aliskiren) with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, aiming to identify specific areas of interest for intervention and the best possible treatment option.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Immunology
Jiuyang Xu, Yaqun Teng, Lianhan Shang, Xiaoying Gu, Guohui Fan, Yijun Chen, Ran Tian, Shuyang Zhang, Bin Cao
Summary: The study found no association between prior use of ACEI/ARB and the risk of COVID-19 infection, and using ACEI/ARB did not change the severity of the disease among patients. This suggests that the current medical guidelines and position statements supporting the continuation of ACEI/ARB use are evidence-based and appropriate.
CLINICAL INFECTIOUS DISEASES
(2021)
